ADMA Biologics, Inc. provided revenue guidance for the remainder of 2022. Over the remainder of 2022, the company expects to deliver significant revenue growth and market share gains for the company's product portfolio, improve margins as operating leverage is realized, and continue to prioritize the exploration of strategic alternatives, to maximize stockholder value.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.655 USD | +0.57% | +6.81% | +115.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+115.04% | 2.23B | |
-2.99% | 89.49B | |
+2.50% | 40.67B | |
-13.54% | 33.15B | |
+62.42% | 26.45B | |
-20.04% | 14.69B | |
-7.93% | 12.89B | |
-12.64% | 11.54B | |
-43.92% | 11.34B | |
+3.97% | 8.84B |
- Stock Market
- Equities
- ADMA Stock
- News ADMA Biologics, Inc.
- ADMA Biologics, Inc. Provides Revenue Guidance for the Remainder of 2022